In response to Drs. Dubben, beck-bornholdt, and logie

International journal of radiation oncology, biology, physics

Volumn 52, Issue 4, 2002, Pages 1148-1150

  Ang, K Kian ^a   Berkey, Brian A ^b   Pajak, Thomas F ^b   Fu, Karen K ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RTOG Statistical Unit   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL KINETICS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; LETTER; MATHEMATICAL MODEL; ONCOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; TREATMENT OUTCOME; VALIDATION PROCESS; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; RADIATION INJURY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TIME;

DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION INJURIES; RADIOTHERAPY; TIME FACTORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037086172     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02777-8     Document Type: Letter

References (11)

1. H.H. Dubben H.P. Beck-Bornholdt A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard-fractionation radiotherapy for head-and-neck squamous cell carcinomas: First report of RTOG 9003 In regard to Fu et al. IJROBP 2000;48:7–16. Actuarial estimates of late normal-tissue effects … now! Int J Radiat Oncol Biol Phys 51 2001 563
2. Logie MB. Regarding Fu et al., A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys In press.
3. K.K. Fu T.F. Pajak A. Trotti A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas First report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
4. E.L. Kaplan P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
5. J. Kalbfleish R. Prentice The statistical analysis of failure time data 1980 John Wiley and Sons New York
6. M. Baumann S.M. Bentzen K.K. Ang Hyperfractionated radiotherapy in head and neck cancer A second look at the clinical data Radiother Oncol 46 1998 127 130
7. C.E. Bonferroni Teoria statistica delle classi e calcolo delle probabilita Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze 8 1936 3 62
8. S. El-Sayed N. Nelson Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region A meta-analysis of prospective and randomised trials J Clin Oncol 14 1996 838 847
9. D.J. Adelstein G.L. Adams Y. Li A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC) An intergroup study (Abstract) Proceedings of ASCO 19 2000 411a
10. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 5 1966 163 170
11. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154